Updated ABCs framework gives clinicians a clearer path to prevent heart disease

By Vijay Kumar MalesuReviewed by Susha Cheriyedath, M.Sc.Jul 7 2026

From PREVENT™ risk scoring to CKM care and healthy aging, the updated ABCs framework turns complex cardiovascular guidance into a practical roadmap for preventing disease across the lifespan.

The ABCs of cardiovascular disease prevention: communicating what we know in 2026. Image Credit: New Africa / Shutterstock

In a recent 'State-of-the-Art' review published in the American Journal of Preventive Cardiology, a group of authors provided an updated, evidence-based framework to help clinicians implement contemporary strategies for the prevention and management of cardiovascular disease (CVD) across diverse clinical settings.

Background

CVD has remained a major public health concern globally, despite advances in prevention and treatment. There is an alarming rise in CVD risk factors, such as obesity, hypertension, and diabetes, driven in part by population aging and the obesity epidemic. Although modern assessment methods, changes in lifestyle, and new medications can help in reducing the risk of CVD, many essential recommendations still go unimplemented. Strengthening the adoption of evidence-based prevention strategies remains essential to improve cardiovascular outcomes. Further research is needed to optimize the implementation of preventive recommendations across healthcare settings.

Early Risk Assessment and Personalized Prevention

Effective CVD prevention starts with identifying individuals who are at increased risk before symptoms or complications occur. The updated framework recommends using the Predicting Risk of Cardiovascular Disease Events (PREVENT™) equations developed by the American Heart Association (AHA). Built from data on nearly 6.5 million adults aged 30-79 years, these equations estimate 10-year risks for CVD, atherosclerotic CVD, and heart failure, as well as 30-year risks in adults up to age 60, while incorporating contemporary risk factors such as the Cardiovascular-Kidney-Metabolic (CKM) syndrome and the social deprivation index. Because PREVENT™ estimates are often 40-50% lower than pooled cohort estimates, individualized interpretation remains important to avoid undertreatment in selected patients.

Risk estimation should be complemented by evaluating risk enhancers, including elevated lipoprotein(a), high-sensitivity C-reactive protein, persistent low-density lipoprotein cholesterol of 160 mg/dL or higher, family history, inflammatory disorders, pregnancy-related complications, cardio-oncologic exposures, and frailty. For individuals with borderline or intermediate risk, coronary artery calcium (CAC) scoring can further refine treatment decisions. The framework also incorporates Life's Essential 8, promoting a healthy diet, physical activity, adequate sleep, tobacco avoidance, healthy weight, and optimal control of blood pressure, cholesterol, and blood glucose to support lifelong cardiovascular health.

Preventive Pharmacotherapy and Blood Pressure Control

The updated framework outlines evidence-based recommendations for preventive medications based on individual cardiovascular risk. Aspirin should be considered only for carefully selected adults aged 40-70 years who have elevated cardiovascular risk without a high likelihood of bleeding. Individuals with CAC scores of 100 or higher, particularly 400 or higher, may derive greater benefit from aspirin for primary prevention. For patients with established CVD, antiplatelet therapy should be tailored according to both ischemic and bleeding risks. Following percutaneous coronary intervention for acute coronary syndrome, dual antiplatelet therapy is generally recommended for up to 12 months, with treatment duration adjusted according to clinical circumstances.

The framework also reinforces strict blood pressure control, targeting levels at or below 130/80 mm Hg through lifestyle modification and medication when indicated. Pharmacological treatment is recommended for high-risk individuals, including those with clinical CVD, chronic kidney disease, diabetes, or elevated 10-year PREVENT™ risk, while others should first undergo 3-6 months of lifestyle intervention supported by home monitoring and team-based care to achieve sustained blood pressure control.

Addressing Obesity and Cholesterol to Reduce Long-Term Risk

Obesity affects more than 40% of adults in the United States and substantially increases the risk of CVD. The new recommendations indicate that clinical obesity assessment should incorporate BMI, waist circumference, other measures of excess body fat, and evidence of organ dysfunction or functional limitation rather than body weight alone. Clinical evaluation should involve diagnosis for heart failure, obstructive sleep apnea, metabolic syndrome, hepatic steatosis, venous and thromboembolic complications, and atrial fibrillation. Lifestyle modification remains the primary treatment, with a target of achieving>5% weight loss. Selected individuals with obesity and elevated cardiovascular risk may also benefit from glucagon-like peptide-1 receptor agonists, which have demonstrated cardiovascular benefits in addition to weight reduction.

Cholesterol management has also evolved toward earlier and more personalized treatment. Lipid profiles should be checked during childhood, around ages 9-11, again at ages 19-21, and at least every five years thereafter. Lipoprotein(a) should be measured at least once during a person's lifetime. Risk-based treatment includes lifestyle modification, statin therapy, and combination lipid-lowering therapies when cholesterol goals are not achieved. Lower low-density lipoprotein cholesterol targets are recommended for individuals at progressively higher cardiovascular risk, reinforcing the importance of early intervention before irreversible arterial damage occurs.

Lifestyle Modification and Risk Factor Management

Sustained lifestyle changes are central to reducing CVD risk alongside appropriate medical therapy. The framework recommends evaluating tobacco and alcohol use during every clinical visit because tobacco exposure and excessive alcohol intake are important modifiable cardiovascular risk factors. Smoking, exposure to secondhand smoke, electronic cigarettes, and vaping contribute to CVD, while excessive alcohol intake promotes inflammation and damages blood vessels. Healthcare professionals should assess patients' readiness to quit and provide behavioral counseling together with evidence-based pharmacological therapies. Recommended treatments include nicotine replacement therapy, varenicline, or bupropion for tobacco cessation, and naltrexone or acamprosate for alcohol dependence. Continuous follow-up is encouraged to improve long-term cessation outcomes.

Cardiometabolic Health and Preventive Strategies

The framework highlights the strong connection between diabetes, chronic kidney disease, metabolic disorders, and cardiovascular health through CKM syndrome. Adults without diabetes risk factors should begin diabetes screening at 35 years of age and repeat testing every three years, with hemoglobin A1c often used for screening. In patients with type 2 diabetes, eGFR and UACR should also be assessed to identify kidney involvement and guide CKM risk management. Management also emphasizes Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and plant-based diets, calorie reduction, and regular physical activity of at least 150 minutes of moderate or 75 minutes of vigorous exercise weekly, along with resistance training twice a week.

The framework further recommends assessing physical and cognitive function during healthy aging, using frailty and cognition screening where appropriate, initiating prompt treatment for stage B pre-heart failure and stage C heart failure using guideline-directed medical therapy, and managing atrial fibrillation with appropriate anticoagulation and early rhythm-control strategies. It also highlights shared decision-making, cardiac rehabilitation, and attention to health-related social needs as part of preventive care across the life course. Together, these measures promote personalized, multidisciplinary cardiovascular prevention throughout life.

Conclusion

The updated CVD Prevention framework provides clinicians with a practical, evidence-based approach for translating current prevention guidelines into everyday clinical practice. The framework focuses on risk assessment, lifestyle modifications, timely pharmacotherapy, and personalized patient clinical care and encompasses a complete range of CVD prevention activities. As an organized structure, the model allows for consistent decision-making and facilitates collaboration between multiple specialties and care teams in different healthcare organizations. The broader use of the ABCs of CVD Prevention model may improve cardiovascular prevention by supporting consistent clinical decision-making, patient-centered care, and uptake of evidence-based recommendations.